QIAGEN, a German provider of sample and assay technologies, agreed to acquire a 96% stake in BLIRT, a biotechnology company. Financial terms were not disclosed. "Thanks to QIAGEN, the growth of BLIRT will accelerate. First and foremost, the scale of operations will increase, and our employees will become part of a global team. We accepted QIAGEN's offer because it would benefit everyone involved: both companies, customers, distributors and employees. I am confident that we will observe positive synergy effects from the joint operations of QIAGEN and BLIRT in the upcoming years. This will create exciting new possibilities. Among other things, customers will have access to a broader offer, and employees will take advantage of new career options," Marian Popinigis, BLIRT CEO.